TASK DEFINITION: In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
PROBLEM: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Regulatory Transparency, Patient 
Access, and Effective Drug Enforcement Act of 2014''.

SEC. 2. SCHEDULING OF SUBSTANCES INCLUDED IN NEW FDA-APPROVED DRUGS.

    Section 201 of the Controlled Substances Act (21 U.S.C. 811) is 
amended by inserting after subsection (h) the following:
    ``(i) Within 45 days of receiving a recommendation from the 
Secretary to add a drug or substance that has never been marketed in 
the United States to a schedule under this title, the Attorney General 
shall, without regard to the findings required by subsection (a) of 
this section or section 202(b), issue an interim final rule, under the 
exception for good cause described in subparagraph (B) of section 
553(b) of title 5, United States Code, placing the drug or substance 
into the schedule recommended by the Secretary. The interim final rule 
shall be made immediately effective under section 553(d)(3) of title 5, 
United States Code.''.

SEC. 3. ENHANCING NEW DRUG DEVELOPMENT.

    Section 302 of the Controlled Substances Act (21 U.S.C. 822) is 
amended by inserting after subsection (g) the following:
    ``(h)(1) A person who submits an application for registration to 
manufacture or distribute a controlled substance in accordance with 
this section may indicate on the registration application that the 
substance will be used only in connection with clinical trials of a 
drug in accordance with section 505(i) of the Federal Food, Drug, and 
Cosmetic Act.
    ``(2) When an application for registration to manufacture or 
distribute a controlled substance includes an indication that the 
controlled substance will be used only in connection with clinical 
trials of a drug in accordance with section 505(i) of the Federal Food, 
Drug, and Cosmetic Act, the Attorney General shall--
            ``(A) make a final decision on the application for 
        registration within 180 days; or
            ``(B) provide notice to the applicant in writing of--
                    ``(i) the outstanding issues that must be resolved 
                in order to reach a final decision on the application; 
                and
                    ``(ii) the estimated date on which a final decision 
                on the application will be made.''.

SEC. 4. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.

    (a) Definitions.--
            (1) Factors as may be relevant to and consistent with the 
        public health and safety.--Section 303 of the Controlled 
        Substances Act (21 U.S.C. 823) is amended by adding at the end 
        the following:
    ``(i) In this section, the phrase `factors as may be relevant to 
and consistent with the public health and safety' means factors that 
are relevant to and consistent with the findings contained in section 
101.''.
            (2) Imminent danger to the public health or safety.--
        Section 304(d) of the Controlled Substances Act (21 U.S.C. 
        824(d)) is amended--
                    (A) by striking ``(d) The Attorney General'' and 
                inserting ``(d)(1) The Attorney General''; and
                    (B) by adding at the end the following:
    ``(2) In this subsection, the phrase `imminent danger to the public 
health or safety' means that, in the absence of an immediate suspension 
order, controlled substances will continue to be distributed or 
dispensed by a registrant who knows or should know through fulfilling 
the obligations of the registrant under this Act, or has reason to 
believe that--
            ``(A) the dispensing is outside the usual course of 
        professional practice;
            ``(B) the distribution or dispensing poses a present or 
        foreseeable risk of adverse health consequences or death due to 
        the abuse or misuse of the controlled substances; or
            ``(C) the controlled substances will continue to be 
        diverted outside of legitimate distribution channels.''.
    (b) Opportunity To Submit Corrective Action Plan Prior to 
Revocation or Suspension.--Subsection (c) of section 304 of the 
Controlled Substances Act (21 U.S.C. 824) is amended--
            (1) by striking the last two sentences;
            (2) by striking ``(c) Before'' and inserting ``(c)(1) 
        Before''; and
            (3) by adding at the end the following:
    ``(2) An order to show cause under paragraph (1) shall--
            ``(A) contain a statement of the basis for the denial, 
        revocation, or suspension, including specific citations to any 
        laws or regulations alleged to be violated by the applicant or 
        registrant;
            ``(B) direct the applicant or registrant to appear before 
        the Attorney General at a time and place stated in the order, 
        but not less than 30 days after the date of receipt of the 
        order; and
            ``(C) notify the applicant or registrant of the opportunity 
        to submit a corrective action plan on or before the date of 
        appearance.
    ``(3) Upon review of any corrective action plan submitted by an 
applicant or registrant pursuant to paragraph (2), the Attorney General 
shall determine whether denial, revocation or suspension proceedings 
should be discontinued, or deferred for the purposes of modification, 
amendment, or clarification to such plan.
    ``(4) Proceedings to deny, revoke, or suspend shall be conducted 
pursuant to this section in accordance with subchapter II of chapter 5 
of title 5, United States Code. Such proceedings shall be independent 
of, and not in lieu of, criminal prosecutions or other proceedings 
under this title or any other law of the United States.
    ``(5) The requirements of this subsection shall not apply to the 
issuance of an immediate suspension order under subsection (d).''.

SEC. 5. REPORT TO CONGRESS ON EFFECTS OF LAW ENFORCEMENT ACTIVITIES ON 
              PATIENT ACCESS TO MEDICATIONS.

    (a) In General.--Not later than 1 year after the date of enactment 
of this Act, the Secretary of Health and Human Services, acting through 
the Commissioner of Food and Drugs and the Director of the Centers for 
Disease Control and Prevention, and in consultation with the 
Administrator of the Drug Enforcement Administration and the Director 
of National Drug Control Policy, shall submit a report to the 
Committees on the Judiciary of the House of Representatives, the 
Committee on Energy and Commerce of the House of Representatives, the 
Committee on the Judiciary of the Senate, and the Committee on Health, 
Education, Labor and Pensions of the Senate identifying--
            (1) obstacles to legitimate patient access to controlled 
        substances;
            (2) issues with diversion of controlled substances; and
            (3) how collaboration between Federal, State, local, and 
        tribal law enforcement agencies and the pharmaceutical industry 
        can benefit patients and prevent diversion and abuse of 
        controlled substances.
    (b) Consultation.--The report under subsection (a) shall 
incorporate feedback and recommendations from the following:
            (1) Patient groups.
            (2) Pharmacies.
            (3) Drug manufacturers.
            (4) Common or contract carriers and warehousemen.
            (5) Hospitals, physicians, and other health care providers.
            (6) State attorneys general.
            (7) Federal, State, local, and tribal law enforcement 
        agencies.
            (8) Health insurance providers and entities that provide 
        pharmacy benefit management services on behalf of a health 
        insurance provider.
            (9) Wholesale drug distributors.

SOLUTION: Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 - Amends the Controlled Substances Act to direct the Attorney General, within 45 days of receiving a recommendation from the Secretary of Health and Human Services (HHS) to add a drug or substance that has never been marketed in the United States to a schedule of controlled substances, to issue an interim final rule under the exception for good cause, placing it into the schedule recommended, effective immediately. Allows a person who submits an application for registration to manufacture or distribute a controlled substance to indicate on the registration application that the substance will be used only in connection with clinical trials of a drug. Requires the Attorney General to: (1) make a final decision on such application within 180 days, or (2) provide written notice to the applicant of the outstanding issues that must be resolved to reach a final decision and the estimated date on which such decision will be made. Defines: (1) "factors as may be relevant to and consistent with the public health and safety," and (2) "imminent danger to the public health or safety." Requires an order to show cause as to why a registration should not be denied, revoked, or suspended to notify the registrant of the opportunity to submit a corrective action plan on or before the date of appearance before the Attorney General. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modification or clarification of such plan. Makes these requirements inapplicable to the issuance of an immediate suspension order. Directs the Secretary, acting through the Commissioner of Food and Drugs (FDA) and the Director of the Centers for Disease Control and Prevention (CDC), to identify: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

PROBLEM: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Drug Competition Act of 2002''.

SEC. 2. FINDINGS.

    Congress finds that--
            (1) prescription drug prices are increasing at an alarming 
        rate and are a major worry of many senior citizens and American 
        families;
            (2) there is a potential for companies with patent rights 
        regarding brand name drugs and companies which could 
        manufacture generic versions of such drugs to enter into 
        financial deals that could tend to restrain trade and greatly 
        reduce competition and increase prescription drug expenditures 
        for American citizens; and
            (3) enhancing competition among these companies can 
        significantly reduce prescription drug expenditures for 
        Americans.

SEC. 3. PURPOSES.

    The purposes of this Act are--
            (1) to provide timely notice to the Department of Justice 
        and the Federal Trade Commission regarding agreements between 
        companies with patent rights regarding brand name drugs and 
        companies which could manufacture generic versions of such 
        drugs; and
            (2) by providing timely notice, to enhance the 
        effectiveness and efficiency of the enforcement of the 
        antitrust and competition laws of the United States.

SEC. 4. DEFINITIONS.

    In this Act:
            (1) ANDA.--The term ``ANDA'' means an Abbreviated New Drug 
        Application, as defined under section 201(aa) of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 321(aa)).
            (2) Assistant attorney general.--The term ``Assistant 
        Attorney General'' means the Assistant Attorney General in 
        charge of the Antitrust Division of the Department of Justice.
            (3) Brand name drug.--The term ``brand name drug'' means a 
        drug approved under section 505(c) of the Federal Food, Drug, 
        and Cosmetic Act (21 U.S.C. 355(c)).
            (4) Brand name drug company.--The term ``brand name drug 
        company'' means the party that received Food and Drug 
        Administration approval to market a brand name drug pursuant to 
        an NDA, where that drug is the subject of an ANDA, or a party 
        owning or controlling enforcement of any patent listed in the 
        Approved Drug Products With Therapeutic Equivalence Evaluations 
        of the Food and Drug Administration for that drug, under 
        section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 355(b)).
            (5) Commission.--The term ``Commission'' means the Federal 
        Trade Commission.
            (6) Generic drug.--The term ``generic drug'' means a 
        product that the Food and Drug Administration has approved 
        under section 505(j) of the Federal Food, Drug, and Cosmetic 
        Act (21 U.S.C. 355(j)).
            (7) Generic drug applicant.--The term ``generic drug 
        applicant'' means a person who has filed or received approval 
        for an ANDA under section 505(j) of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 355(j)).
            (8) NDA.--The term ``NDA'' means a New Drug Application, as 
        defined under section 505(b) et seq. of the Federal Food, Drug, 
        and Cosmetic Act (21 U.S.C. 355(b) et seq.)

SEC. 5. NOTIFICATION OF AGREEMENTS.

    (a) In General.--
            (1) Requirement.--A generic drug applicant that has 
        submitted an ANDA containing a certification under section 
        505(j)(2)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act 
        (21 U.S.C. 355(j)(2)(vii)(IV)) and a brand name drug company 
        that enter into an agreement described in paragraph (2), prior 
        to the generic drug that is the subject of the application 
        entering the market, shall each file the agreement as required 
        by subsection (b).
            (2) Definition.--An agreement described in this paragraph 
        is an agreement regarding--
                    (A) the manufacture, marketing or sale of the brand 
                name drug that is the subject of the generic drug 
                applicant's ANDA;
                    (B) the manufacture, marketing or sale of the 
                generic drug that is the subject of the generic drug 
                applicant's ANDA; or
                    (C) the 180-day period referred to in section 
                505(j)(5)(B)(iv) of the Federal Food, Drug, and 
                Cosmetic Act (21 U.S.C. 355(j)(5)(B)(iv)) as it applies 
                to such ANDA or to any other ANDA based on the same 
                brand name drug.
    (b) Filing.--
            (1) Agreement.--The generic drug applicant and the brand 
        name drug company entering into an agreement described in 
        subsection (a)(2) shall file with the Assistant Attorney 
        General and the Commission the text of any such agreement, 
        except that the generic drug applicant and the brand-name drug 
        company shall not be required to file an agreement that solely 
        concerns--
                    (A) purchase orders for raw material supplies;
                    (B) equipment and facility contracts;
                    (C) employment or consulting contracts; or
                    (D) packaging and labeling contracts.
            (2) Other agreements.--The generic drug applicant and the 
        brand name drug company entering into an agreement described in 
        subsection (a)(2) shall file with the Assistant Attorney 
        General and the Commission the text of any other agreements not 
        described in subsection (a)(2) between the generic drug 
        applicant and the brand name drug company which are contingent 
        upon, provide a contingent condition for, or are otherwise 
        related to an agreement which must be filed under this Act.
            (3) Description.--In the event that any agreement required 
        to be filed by paragraph (1) or (2) has not been reduced to 
        text, both the generic drug applicant and the brand name drug 
        company shall file written descriptions of the non-textual 
        agreement or agreements that must be filed sufficient to reveal 
        all of the terms of the agreement or agreements.

SEC. 6. FILING DEADLINES.

    Any filing required under section 5 shall be filed with the 
Assistant Attorney General and the Commission not later than 10 
business days after the date the agreements are executed.

SEC. 7. DISCLOSURE EXEMPTION.

    Any information or documentary material filed with the Assistant 
Attorney General or the Commission pursuant to this Act shall be exempt 
from disclosure under section 552 of title 5, and no such information 
or documentary material may be made public, except as may be relevant 
to any administrative or judicial action or proceeding. Nothing in this 
section is intended to prevent disclosure to either body of Congress or 
to any duly authorized committee or subcommittee of the Congress.

SEC. 8. ENFORCEMENT.

    (a) Civil Penalty.--Any brand name drug company or generic drug 
applicant which fails to comply with any provision of this Act shall be 
liable for a civil penalty of not more than $11,000, for each day 
during which such entity is in violation of this Act. Such penalty may 
be recovered in a civil action brought by the United States, or brought 
by the Commission in accordance with the procedures established in 
section 16(a)(1) of the Federal Trade Commission Act (15 U.S.C. 56(a)).
    (b) Compliance and Equitable Relief.--If any brand name drug 
company or generic drug applicant fails to comply with any provision of 
this Act, the United States district court may order compliance, and 
may grant such other equitable relief as the court in its discretion 
determines necessary or appropriate, upon application of the Assistant 
Attorney General or the Commission.

SEC. 9. RULEMAKING.

    The Commission, with the concurrence of the Assistant Attorney 
General and by rule in accordance with section 553 of title 5 United 
States Code, consistent with the purposes of this Act--
            (1) may define the terms used in this Act;
            (2) may exempt classes of persons or agreements from the 
        requirements of this Act; and
            (3) may prescribe such other rules as may be necessary and 
        appropriate to carry out the purposes of this Act.

SEC. 10. SAVINGS CLAUSE.

    Any action taken by the Assistant Attorney General or the 
Commission, or any failure of the Assistant Attorney General or the 
Commission to take action, under this Act shall not bar any proceeding 
or any action with respect to any agreement between a brand name drug 
company and a generic drug applicant at any time under any other 
provision of law, nor shall any filing under this Act constitute or 
create a presumption of any violation of any antitrust or competition 
laws.

SEC. 11. EFFECTIVE DATE.

    This Act shall--
            (1) take effect 30 days after the date of enactment of this 
        Act; and
            (2) shall apply to agreements described in section 5 that 
        are entered into 30 days after the date of enactment of this 
        Act.

            Passed the Senate November 18, 2002.

            Attest:

                                                  JERI THOMSON,

                                                             Secretary.

SOLUTION: Drug Competition Act of 2002 - (Sec. 5) Requires a generic drug applicant that has submitted an Abbreviated New Drug Application (ANDA) and a brand name drug company that enter into an agreement, prior to the generic drug entering the market, regarding the manufacture, marketing, or sale of the brand name or the generic drug, or regarding the 180-day semi-exclusivity period referred to in the Federal Food, Drug, and Cosmetic Act as it applies to such ANDA or any other ANDA based on the same brand name drug, to each file such agreement and any related agreements with the Assistant Attorney General and the Federal Trade Commission (FTC). Makes an exception for agreements that solely concern purchase orders for raw material supplies, equipment and facility contracts, or employment or consulting contracts. Requires such agreements to be filed not later than ten business days after the date they are executed.(Sec. 7) Exempts any such information or documentary material filed from disclosure under the Freedom of Information Act. Prohibits such information or material from being made public, except as relevant to any administrative or judicial action or proceeding.(Sec. 8) Subjects an applicant or company to a civil penalty of up to $11,000 for each day such entity fails to comply with this Act, recoverable in a civil action brought by the United States or the FTC. Authorizes a U.S. district court to order compliance and grant equitable relief.

PROBLEM: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Surface Transportation Extension Act 
of 2005, Part VI''.

SEC. 2. ADMINISTRATIVE EXPENSES FOR FEDERAL-AID HIGHWAY PROGRAM.

    (a) Authorization of Contract Authority.--Section 4(a) of the 
Surface Transportation Extension Act of 2004, Part V (118 Stat. 1147, 
119 Stat. 325) is amended by striking ``$292,179,920'' and inserting 
``$309,260,880''.
    (b) Limitation on Obligations.--Of the obligation limitation made 
available for Federal-aid highways and highway safety construction 
programs for fiscal year 2005 by division H of Public Law 108-447 (118 
Stat. 3204) not more than $17,080,960 shall be available, in addition 
to any obligation limitation previously provided, for administrative 
expenses of the Federal Highway Administration for the period of July 
30, 2005, through August 14, 2005.
    (b) Conforming Amendment.--Section 2(e)(3) of such Act (118 Stat. 
1146, 119 Stat. 325) is amended by striking ``July 30'' and inserting 
``August 14''.

SEC. 3. ADMINISTRATIVE EXPENSES FOR NATIONAL HIGHWAY TRAFFIC SAFETY 
              ADMINISTRATION.

    (a) In General.--There shall be available from the Highway Trust 
Fund (other than the Mass Transit Account) for the Secretary of 
Transportation to pay the administrative expenses of the National 
Highway Traffic Administration in carrying out the highway safety 
programs authorized by sections 157 and 163 of chapter 1 of title 23, 
United States Code, and sections 402, 403, 405, and 410 of chapter 4 of 
such title, the National Driver Register under chapter 303 of title 49, 
United States Code, the motor vehicle safety program under chapter 301 
of such title 49, and the motor vehicle information and cost savings 
program under part C of subtitle VI of such title 49 $4,125,000 for the 
period of July 30, 2005, through August 14, 2005.
    (b) Contract Authority.--Funds made available by this section shall 
be available for obligation in the same manner as if such funds were 
apportioned under chapter 1 of title 23, United States Code; except 
that such funds shall remain available until expended.

SEC. 4. ADMINISTRATIVE EXPENSES FOR MOTOR CARRIER SAFETY ADMINISTRATION 
              PROGRAM.

    Section 7(a)(1) of the Surface Transportation Extension Act of 
2004, Part V (118 Stat. 1153; 119 Stat. 330) is amended--
        (1) by striking ``$213,799,290'' and inserting 
    ``$224,383,414''; and
        (2) by striking ``July 30'' and inserting ``August 14''.

SEC. 5. ADMINISTRATIVE EXPENSES FOR FEDERAL TRANSIT PROGRAMS.

    (a) Authorization of Appropriations.--Section 5338(f)(2) of title 
49, United States Code, is amended--
        (1) in the heading by striking ``july 30'' and inserting 
    ``august 14'';
        (2) in subparagraph (A)(vii)--
            (A) by striking ``$54,350,686'' and inserting 
        ``$57,650,686''; and
            (B) by striking ``July 30'' and inserting ``August 14''; 
        and
        (3) in subparagraph (B)(vii) by striking ``July 30'' and 
    inserting ``August 14''.
    (b) Obligation Ceiling.--Section 3040(7) of the Transportation 
Equity Act for the 21st Century (112 Stat. 394; 118 Stat. 885; 118 
Stat. 1158; 119 Stat. 333) is amended--
        (1) by striking ``$6,398,695,996'' and inserting 
    ``$6,401,995,996''; and
        (2) by striking ``July 30'' and inserting ``August 14''.

SEC. 6. BUREAU OF TRANSPORTATION STATISTICS.

    (a) In General.--Section 5001(a)(4) of the Transportation Equity 
Act for the 21st Century (112 Stat. 420; 118 Stat. 1150; 119 Stat. 327; 
119 Stat. 346; 119 Stat. 379; 119 Stat. 394) is amended by striking 
``$25,730,000 for the period of October 1, 2004, through July 30, 
2005'' and inserting ``$27,000,000 for the period of October 1, 2004, 
through August 14, 2005''.
    (b) Limitation on Obligations.--Of the obligation limitation made 
available for Federal-aid highways and highway safety construction 
programs for fiscal year 2005 by division H of Public Law 108-447 (118 
Stat. 3204) not more than $1,270,000 shall be available, in addition to 
any obligation limitation previously provided, for administrative 
expenses of the Bureau of Transportation Statistics for the period of 
July 30, 2005, through August 14, 2005.

SEC. 7. EXTENSION OF AUTHORIZATION FOR USE OF TRUST FUNDS FOR 
              OBLIGATIONS UNDER TEA-21.

    (a) Highway Trust Fund.--
        (1) In general.--Paragraph (1) of section 9503(c) of the 
    Internal Revenue Code of 1986 is amended--
            (A) in the matter before subparagraph (A), by striking 
        ``July 31, 2005'' and inserting ``August 15, 2005'',
            (B) by striking ``or'' at the end of subparagraph (O),
            (C) by striking the period at the end of subparagraph (P) 
        and inserting ``, or'',
            (D) by inserting after subparagraph (P) the following new 
        subparagraph:
            ``(Q) authorized to be paid out of the Highway Trust Fund 
        under the Surface Transportation Extension Act of 2005, Part 
        VI.'', and
            (E) in the matter after subparagraph (Q), as added by this 
        paragraph, by striking ``Surface Transportation Extension Act 
        of 2005, Part V'' and inserting ``Surface Transportation 
        Extension Act of 2005, Part VI''.
        (2) Mass transit account.--Paragraph (3) of section 9503(e) of 
    such Code is amended--
            (A) in the matter before subparagraph (A), by striking 
        ``July 31, 2005'' and inserting ``August 15, 2005'',
            (B) in subparagraph (M), by striking ``or'' at the end of 
        such subparagraph,
            (C) in subparagraph (N), by inserting ``or'' at the end of 
        such subparagraph,
            (D) by inserting after subparagraph (N) the following new 
        subparagraph:
            ``(O) the Surface Transportation Extension Act of 2005, 
        Part VI,'', and
            (E) in the matter after subparagraph (O), as added by this 
        paragraph, by striking ``Surface Transportation Extension Act 
        of 2005, Part V'' and inserting ``Surface Transportation 
        Extension Act of 2005, Part VI''.
        (3) Exception to limitation on transfers.--Subparagraph (B) of 
    section 9503(b)(6) of such Code is amended by adding at the end the 
    following: ``The preceding sentence shall be applied by 
    substituting `August 15, 2005' for the date therein.''.
    (b) Aquatic Resources Trust Fund.--
        (1) Sport fish restoration account.--Paragraph (2) of section 
    9504(b) of the Internal Revenue Code of 1986 is amended by adding 
    at the end the following: ``Subparagraphs (A), (B), and (C) shall 
    each be applied by substituting `Surface Transportation Extension 
    Act of 2005, Part VI' for `Surface Transportation Extension Act of 
    2005, Part V'.''.
        (2) Boat safety account.--Subsection (c) of section 9504 of 
    such Code is amended--
            (A) by striking ``July 31, 2005'' and inserting ``August 
        15, 2005'', and
            (B) by striking ``Surface Transportation Extension Act of 
        2005, Part V'' and inserting ``Surface Transportation Extension 
        Act of 2005, Part VI''.
        (3) Exception to limitation on transfers.--Paragraph (2) of 
    section 9504(d) of such Code is amended by adding at the end the 
    following new sentence: ``The preceding sentence shall be applied 
    by substituting `August 15, 2005' for the date therein.''.
    (c) Temporary Rule Regarding Adjustments.--During the period 
beginning on the date of the enactment of the Surface Transportation 
Extension Act of 2003 and ending on August 14, 2005, for purposes of 
making any estimate under section 9503(d) of the Internal Revenue Code 
of 1986 of receipts of the Highway Trust Fund, the Secretary of the 
Treasury shall treat--
        (1) each expiring provision of paragraphs (1) through (4) of 
    section 9503(b) of such Code which is related to appropriations or 
    transfers to such Fund to have been extended through the end of the 
    24-month period referred to in section 9503(d)(1)(B) of such Code, 
    and
        (2) with respect to each tax imposed under the sections 
    referred to in section 9503(b)(1) of such Code, the rate of such 
    tax during the 24-month period referred to in section 9503(d)(1)(B) 
    of such Code to be the same as the rate of such tax as in effect on 
    the date of the enactment of the Surface Transportation Extension 
    Act of 2003.
    (d) Subsequent Repeal of Certain Temporary Provisions.--Each of the 
following provisions of the Internal Revenue Code of 1986 are amended 
by striking the last sentence thereof:
        (1) Section 9503(b)(6)(B).
        (2) Section 9504(b)(2).
        (3) Section 9504(d)(2).
    (e) Effective Date.--
        (1) In general.--Except as provided in paragraph (2), the 
    amendments made by this section shall take effect on the date of 
    the enactment of this Act.
        (2) Subsequent repeal.--The amendments made by subsection (d) 
    shall take effect on the date of the enactment of the Safe, 
    Accountable, Flexible, Efficient Transportation Equity Act: A 
    Legacy for Users and shall be executed immediately before the 
    amendments made by such Act.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.

SOLUTION:
Surface Transportation Extension Act of 2005, Part VI - Extends, through August 14, 2005, the authorization of appropriations from the Highway Trust Fund (HTF) for: (1) administrative expenses for federal highway, highway safety, motor carrier safety, and transit programs; and (2) the Bureau of Transportation Statistics. Prohibits, after August 14, 2005, the obligation of funds for any federal-aid highway program project until enactment of a multiyear law reauthorizing the federal-aid highway program.

Amends the Internal Revenue Code to authorize until August 15, 2005, expenditures for obligations under the Transportation Equity Act for the 21st Century (TEA-21) from: (1) the HTF; (2) the Mass Transit Account; and (3) the Aquatic Resources Trust Fund.